KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EBITDA (2018 - 2025)

Adaptive Biotechnologies' EBITDA history spans 8 years, with the latest figure at -$12.8 million for Q4 2025.

  • For Q4 2025, EBITDA fell 156.26% year-over-year to -$12.8 million; the TTM value through Dec 2025 reached -$57.1 million, down 38.57%, while the annual FY2025 figure was $15.2 million, 136.85% up from the prior year.
  • EBITDA for Q4 2025 was -$12.8 million at Adaptive Biotechnologies, down from $10.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $78.9 million in Q4 2023 and bottomed at -$63.1 million in Q1 2022.
  • The 5-year median for EBITDA is -$33.5 million (2023), against an average of -$26.0 million.
  • The largest annual shift saw EBITDA soared 301.31% in 2023 before it crashed 276.06% in 2025.
  • A 5-year view of EBITDA shows it stood at -$61.6 million in 2021, then soared by 36.38% to -$39.2 million in 2022, then soared by 301.31% to $78.9 million in 2023, then tumbled by 71.22% to $22.7 million in 2024, then plummeted by 156.26% to -$12.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's EBITDA are -$12.8 million (Q4 2025), $10.3 million (Q3 2025), and -$25.0 million (Q2 2025).